Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 18/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.42 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6450593 | 1.00 | HPGD (0.48) | HPGDRAB9ANPC1HTTAKR1B1 | |
| SCHEMBL6449229 | 0.85 | HPGD (0.51) | HPGDRAB9ANPC1HTTGSK3B | |
| SCHEMBL6449233 | 0.85 | HPGD (0.51) | HPGDRAB9ANPC1HTTGSK3B | |
| SCHEMBL6447878 | 0.79 | HPGD (0.46) | HPGDRAB9ANPC1HTT | |
| SCHEMBL6447884 | 0.79 | HPGD (0.46) | HPGDRAB9ANPC1HTT | |
| SCHEMBL6449303 | 0.78 | PTGS1 (0.47) | HPGDRAB9ANPC1HTTAKR1B1 | |
| SCHEMBL6449306 | 0.78 | PTGS1 (0.47) | HPGDRAB9ANPC1HTTAKR1B1 | |
| SCHEMBL6457211 | 0.77 | HPGD (0.44) | HPGDRAB9ANPC1HTT | |
| SCHEMBL6457208 | 0.77 | HPGD (0.44) | HPGDRAB9ANPC1HTT | |
| SCHEMBL6450388 | 0.77 | PTPN1 (0.57) | HPGDHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014767-A1 | Benzoxazole, benzothiazole, and benzimidazole derivatives for the treatment of cancer and other diseases | INCYTE CORPORATION | 2005-01-20 | — | — | US | disclosed |
| WO-2004066952-A2 | BENZOXAZOLE, BENZOTHIAZOLE, AND BENZIMIDAZOLE DERIVATIVES FOR THE TREATMENT OF CANCER AND OTHER DISEASES | INCYTE CORPORATION (US) | 2004-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014767-A1 | Benzoxazole, benzothiazole, and benzimidazole derivatives for the treatment of cancer and other diseases | AR, CCNT1, BRD1 | HPGD 1202/4885RAB9A 3637/4885NPC1 2072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.